Cargando…

A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer

A key step in providing management/treatment options to men with suspected prostate cancer (PCa) is categorizing the risk in terms of the presence of benign, low-risk, intermediate-risk, or high-risk disease. Our novel modality brings new evidence, based on the long-known hallmark characteristic of...

Descripción completa

Detalles Bibliográficos
Autores principales: Weksler, Meir, Simon, Avi, Lenkinski, Robert E., Landsman, Hagar, Matzkin, Haim, Mabjeesh, Nicola, Leibovitch, Ilan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914539/
https://www.ncbi.nlm.nih.gov/pubmed/36766529
http://dx.doi.org/10.3390/diagnostics13030424
_version_ 1784885689167380480
author Weksler, Meir
Simon, Avi
Lenkinski, Robert E.
Landsman, Hagar
Matzkin, Haim
Mabjeesh, Nicola
Leibovitch, Ilan
author_facet Weksler, Meir
Simon, Avi
Lenkinski, Robert E.
Landsman, Hagar
Matzkin, Haim
Mabjeesh, Nicola
Leibovitch, Ilan
author_sort Weksler, Meir
collection PubMed
description A key step in providing management/treatment options to men with suspected prostate cancer (PCa) is categorizing the risk in terms of the presence of benign, low-risk, intermediate-risk, or high-risk disease. Our novel modality brings new evidence, based on the long-known hallmark characteristic of PCa—decreased zinc (Zn), which is the most direct metabolic sign of malignancy and its aggressiveness. To date, this approach has not been adopted for clinical use for a number of reasons that are described in this article, and which have been addressed by our approach. Zn has to be measured on fresh samples, prior to fixating in formalin; therefore, samples have to be scanned during the biopsy session. As Zn depletion occurs in the glands where the tumors develop, estimation of the glands’ levels in the scanned tissue, along with their compactness, are essential for accurate diagnosis. Combined with the Zn depletion, this facilitates a reliable assessment of disease aggressiveness. Data gathered in the clinical study described here indicate that, in addition to improving the biopsy quality by real-time interactive guidance, a malignancy score can now be established for the entire prostate, allowing higher granularity personalized risk stratification and more decisive treatment decisions for all PCa patients.
format Online
Article
Text
id pubmed-9914539
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99145392023-02-11 A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer Weksler, Meir Simon, Avi Lenkinski, Robert E. Landsman, Hagar Matzkin, Haim Mabjeesh, Nicola Leibovitch, Ilan Diagnostics (Basel) Article A key step in providing management/treatment options to men with suspected prostate cancer (PCa) is categorizing the risk in terms of the presence of benign, low-risk, intermediate-risk, or high-risk disease. Our novel modality brings new evidence, based on the long-known hallmark characteristic of PCa—decreased zinc (Zn), which is the most direct metabolic sign of malignancy and its aggressiveness. To date, this approach has not been adopted for clinical use for a number of reasons that are described in this article, and which have been addressed by our approach. Zn has to be measured on fresh samples, prior to fixating in formalin; therefore, samples have to be scanned during the biopsy session. As Zn depletion occurs in the glands where the tumors develop, estimation of the glands’ levels in the scanned tissue, along with their compactness, are essential for accurate diagnosis. Combined with the Zn depletion, this facilitates a reliable assessment of disease aggressiveness. Data gathered in the clinical study described here indicate that, in addition to improving the biopsy quality by real-time interactive guidance, a malignancy score can now be established for the entire prostate, allowing higher granularity personalized risk stratification and more decisive treatment decisions for all PCa patients. MDPI 2023-01-24 /pmc/articles/PMC9914539/ /pubmed/36766529 http://dx.doi.org/10.3390/diagnostics13030424 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Weksler, Meir
Simon, Avi
Lenkinski, Robert E.
Landsman, Hagar
Matzkin, Haim
Mabjeesh, Nicola
Leibovitch, Ilan
A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer
title A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer
title_full A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer
title_fullStr A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer
title_full_unstemmed A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer
title_short A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer
title_sort novel modality enables new evidence-based individual risk stratification that can potentially lead to decisive management and treatment decisions in prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914539/
https://www.ncbi.nlm.nih.gov/pubmed/36766529
http://dx.doi.org/10.3390/diagnostics13030424
work_keys_str_mv AT wekslermeir anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT simonavi anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT lenkinskiroberte anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT landsmanhagar anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT matzkinhaim anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT mabjeeshnicola anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT leibovitchilan anovelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT wekslermeir novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT simonavi novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT lenkinskiroberte novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT landsmanhagar novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT matzkinhaim novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT mabjeeshnicola novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer
AT leibovitchilan novelmodalityenablesnewevidencebasedindividualriskstratificationthatcanpotentiallyleadtodecisivemanagementandtreatmentdecisionsinprostatecancer